Artelo Biosciences Quote - ARTL

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.20

Bid

1.16

Offer

1.20

Volume

12,006

1.15 Day's Range 1.20

0.91 52 Week Range 1.75

Market Cap

3.873M

Previous Close

1.1642

Open

1.15

Last Trade

1.2

Last Trade Time

07:40:23

Financial Volume

US$ 14,195

VWAP

1.1823

Average Volume (3m)

35,065

Shares Outstanding

3,227,700

Dividend Yield

PE Ratio

-0.42

Earnings Per Share (EPS)

-2.88

Revenue

Net Profit

-9.29M

Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approa... Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.artelobio.com

Headquarters

Fernley, Nevada, USA

Founded

Artelo Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARTL. The last closing price for Artelo Biosciences was US$1.16. Over the last year, Artelo Biosciences shares have traded in a share price range of US$ 0.91 to US$ 1.75.

Artelo Biosciences currently has 3,227,700 shares in issue. The market capitalisation of Artelo Biosciences is US$3.76 million. Artelo Biosciences has a price to earnings ratio (PE ratio) of -0.42.

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif...

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

SOLANA BEACH, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

SOLANA BEACH, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program

SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...

Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.01	-0.826446280992	1.21	1.21	1.12	13366	1.17483503	CS
4	0.17	16.5048543689	1.03	1.21	1.0101	26906	1.13078135	CS
12	0.04	3.44827586207	1.16	1.32	0.91	35065	1.1324041	CS
26	-0.16	-11.7647058824	1.36	1.43	0.91	20407	1.15897483	CS
52	-0.19	-13.6690647482	1.39	1.75	0.91	34892	1.30077389	CS
156	0.83	224.324324324	0.37	7.2	0.2599	226311	1.34468721	CS
260	-1.09	-47.5982532751	2.29	7.2	0.2599	1234562	1.40474691	CS

ARTL - Frequently Asked Questions (FAQ)

What is the current Artelo Biosciences share price?

The current share price of Artelo Biosciences is US$ 1.20

How many Artelo Biosciences shares are in issue?

Artelo Biosciences has 3,227,700 shares in issue

What is the market cap of Artelo Biosciences?

The market capitalisation of Artelo Biosciences is USD 3.76M

What is the 1 year trading range for Artelo Biosciences share price?

Artelo Biosciences has traded in the range of US$ 0.91 to US$ 1.75 during the past year

What is the PE ratio of Artelo Biosciences?

The price to earnings ratio of Artelo Biosciences is -0.42

What is the reporting currency for Artelo Biosciences?

Artelo Biosciences reports financial results in USD

What is the latest annual profit for Artelo Biosciences?

The latest annual profit of Artelo Biosciences is USD -9.29M

What is the registered address of Artelo Biosciences?

The registered address for Artelo Biosciences is 564 WEDGE LANE, FERNLEY, NEVADA, 89408

What is the Artelo Biosciences website address?

The website address for Artelo Biosciences is www.artelobio.com

Which industry sector does Artelo Biosciences operate in?

Artelo Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NVNINVNI Group Ltd	US$ 4.82 (223.49%)	355.02M
EVAXEvaxion Biotech AS	US$ 5.8701 (61.27%)	54.3M
ELABPMGC Holdings Inc	US$ 3.025 (52.78%)	73.91M
NEUPNeuphoria Therapeutics Inc	US$ 5.1801 (48.43%)	24.71M
GOEVCanoo Inc	US$ 0.4835 (46.52%)	275.33M
GODNUGolden Star Acquisition Corporation	US$ 3.57 (-72.24%)	14.27k
GODNGolden Star Acquisition Corporation	US$ 2.91 (-65.91%)	479.33k
NXTTNext Technology Holding Inc	US$ 1.3099 (-56.91%)	2.33M
LSELeishen Energy Holding Company Ltd	US$ 6.60 (-40.62%)	125.66k
SGLYSingularity Future Technology Ltd	US$ 1.62 (-38.64%)	863.44k
ACONAclarion Inc	US$ 0.056 (29.63%)	745.99M
NVNINVNI Group Ltd	US$ 4.79 (221.48%)	355.04M
GOEVCanoo Inc	US$ 0.487 (47.58%)	275.39M
RIMEAlgorhythm Holdings Inc	US$ 0.036 (5.57%)	257.01M
RGTIRigetti Computing Inc	US$ 13.212 (-1.92%)	201.69M